Nonalcoholic Fatty Liver Disease and Fibrosis Associated With Increased Risk of Cardiovascular Events in a Prospective Study.

[1]  E. Guallar,et al.  Non‐alcoholic fatty liver disease and the incidence of myocardial infarction: A cohort study , 2019, Journal of gastroenterology and hepatology.

[2]  Christopher J. N. Kigongo,et al.  Diagnostic Accuracy of Noninvasive Fibrosis Models to Detect Change in Fibrosis Stage. , 2019, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[3]  R. Giugliano,et al.  The nonalcoholic fatty liver disease (NAFLD) fibrosis score, cardiovascular risk stratification and a strategy for secondary prevention with ezetimibe. , 2018, International journal of cardiology.

[4]  M. Manns,et al.  Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030. , 2018, Journal of hepatology.

[5]  A. Micek,et al.  Simple Scores of Fibrosis and Mortality in Patients with NAFLD: A Systematic Review with Meta-Analysis , 2018, Journal of clinical medicine.

[6]  Antonio Felix Conde-Martin,et al.  Fibrosis Severity as a Determinant of Cause-Specific Mortality in Patients With Advanced Nonalcoholic Fatty Liver Disease: A Multi-National Cohort Study. , 2018, Gastroenterology.

[7]  A. Suzuki,et al.  Identifying Nonalcoholic Fatty Liver Disease Advanced Fibrosis in the Veterans Health Administration , 2018, Digestive Diseases and Sciences.

[8]  C. De Vito,et al.  Severity of OSAS, CPAP and cardiovascular events: A follow‐up study , 2018, European journal of clinical investigation.

[9]  L. Henry,et al.  NAFLD AND NASH: Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention , 2018 .

[10]  M. A. Khan,et al.  Beneficial Effects of Statins on the Rates of Hepatic Fibrosis, Hepatic Decompensation, and Mortality in Chronic Liver Disease: A Systematic Review and Meta-Analysis , 2017, The American Journal of Gastroenterology.

[11]  A. Unalp‐Arida,et al.  Liver fibrosis scores predict liver disease mortality in the United States population , 2017, Hepatology.

[12]  V. Wong,et al.  Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta‐analysis , 2017, Hepatology.

[13]  F. Violi,et al.  Under-prescription of statins in patients with non-alcoholic fatty liver disease. , 2017, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[14]  J. Fonseca,et al.  Comment to: "EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease". , 2017, Journal of hepatology.

[15]  M. Allison,et al.  Age as a Confounding Factor for the Accurate Non-Invasive Diagnosis of Advanced NAFLD Fibrosis , 2016, The American Journal of Gastroenterology.

[16]  V. Wong,et al.  Advanced liver fibrosis but not steatosis is independently associated with albuminuria in Chinese patients with type 2 diabetes. , 2017, Journal of hepatology.

[17]  Yingying Ding,et al.  Association of non-alcoholic fatty liver disease with major adverse cardiovascular events: A systematic review and meta-analysis , 2016, Scientific Reports.

[18]  Corrado Barbui,et al.  Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis. , 2016, Journal of hepatology.

[19]  H. Tilg,et al.  EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. , 2016, Journal of hepatology.

[20]  C. Tsioufis,et al.  Metabolic syndrome, independent of its components, affects adversely cardiovascular morbidity in essential hypertensives. , 2016, Atherosclerosis.

[21]  G. Labbadia,et al.  Similar Reduction of Cholesterol-Adjusted Vitamin E Serum Levels in Simple Steatosis and Non-Alcoholic Steatohepatitis , 2015, Clinical and Translational Gastroenterology.

[22]  F. Violi,et al.  Oxidative stress: New insights on the association of non-alcoholic fatty liver disease and atherosclerosis. , 2015, World journal of hepatology.

[23]  A. Farcomeni,et al.  Incidence of myocardial infarction and vascular death in elderly patients with atrial fibrillation taking anticoagulants: relation to atherosclerotic risk factors. , 2015, Chest.

[24]  Mats Fredrikson,et al.  Fibrosis stage is the strongest predictor for disease‐specific mortality in NAFLD after up to 33 years of follow‐up , 2015, Hepatology.

[25]  M. del Ben,et al.  The efficacy and safety of statins for the treatment of non-alcoholic fatty liver disease. , 2015, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[26]  S. Baik,et al.  Invasive and non-invasive diagnosis of cirrhosis and portal hypertension. , 2014, World journal of gastroenterology.

[27]  G. Carpino,et al.  Role of Hepatic Progenitor Cells in Nonalcoholic Fatty Liver Disease Development: Cellular Cross-Talks and Molecular Networks , 2013, International journal of molecular sciences.

[28]  Liao Sun,et al.  Independent Association between Nonalcoholic Fatty Liver Disease and Cardiovascular Disease: A Systematic Review and Meta-Analysis , 2013, International journal of endocrinology.

[29]  T. Therneau,et al.  Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States , 2013, Hepatology.

[30]  F. Angelico,et al.  Non-alcoholic fatty liver disease and cardiovascular disease: epidemiological, clinical and pathophysiological evidences , 2012, Internal and Emergency Medicine.

[31]  Christopher D Byrne,et al.  Non-alcoholic fatty liver disease: a new and important cardiovascular risk factor? , 2012, European heart journal.

[32]  Hani Jneid,et al.  2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/non-ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Forc , 2012, Journal of the American College of Cardiology.

[33]  P. Murchie,et al.  New NICE guidelines for hypertension , 2011, BMJ : British Medical Journal.

[34]  Enzo Bonora,et al.  Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. , 2010, The New England journal of medicine.

[35]  A. Burt,et al.  Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease , 2022 .

[36]  A. Sanyal,et al.  Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. , 2009, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[37]  Yuichi Harano,et al.  The Severity of Ultrasonographic Findings in Nonalcoholic Fatty Liver Disease Reflects the Metabolic Syndrome and Visceral Fat Accumulation , 2007, The American Journal of Gastroenterology.

[38]  T. Therneau,et al.  The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD , 2007, Hepatology.

[39]  Fernando Costa,et al.  Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. , 2005, Circulation.

[40]  D. Kivlahan,et al.  The AUDIT alcohol consumption questions (AUDIT-C): an effective brief screening test for problem drinking. Ambulatory Care Quality Improvement Project (ACQUIP). Alcohol Use Disorders Identification Test. , 1998, Archives of internal medicine.

[41]  H. Sahai,et al.  Formulae and tables for the determination of sample sizes and power in clinical trials for testing differences in proportions for the two-sample design: a review. , 1996, Statistics in medicine.

[42]  Robert A. Zimmerman,et al.  Special report from the National Institute of Neurological Disorders and Stroke. Classification of cerebrovascular diseases III. , 1990, Stroke.

[43]  V. Basevi.  Standards of Medical Care in Diabetes—2011 , 2011, Diabetes Care.